Does Earnings Upgrade Change The Bull Case For CareDx Stock (CDNA)?

Simply Wall St.11-08 13:36

CareDx reported third quarter 2026 revenue of US$139.36 million and net income of US$19.29 million, raised full year 2026 revenue guidance to US$520 million to US$530 million, and highlighted new KOAR...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681844335?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-08 13:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681844335","market":"nz","top_or_hot":-1,"title":"Does Earnings Upgrade Change The Bull Case For CareDx Stock (CDNA)?","media":"Simply Wall St.","content":"<div>\n<p>CareDx reported third quarter 2026 revenue of US$139.36 million and net income of US$19.29 million, raised full year 2026 revenue guidance to US$520 million to US$530 million, and highlighted new KOAR...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/does-earnings-upgrade-change-the-bull-case-for-caredx-stock\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Earnings Upgrade Change The Bull Case For CareDx Stock (CDNA)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Earnings Upgrade Change The Bull Case For CareDx Stock (CDNA)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-08 13:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/does-earnings-upgrade-change-the-bull-case-for-caredx-stock><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CareDx reported third quarter 2026 revenue of US$139.36 million and net income of US$19.29 million, raised full year 2026 revenue guidance to US$520 million to US$530 million, and highlighted new KOAR...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/does-earnings-upgrade-change-the-bull-case-for-caredx-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/does-earnings-upgrade-change-the-bull-case-for-caredx-stock","article_id":"2681844335","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/does-earnings-upgrade-change-the-bull-case-for-caredx-stock","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681844335","pubTimestamp":1794116193,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 8, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx"},"translate_title":"盈利升级会改变 CareDx 股票 (CDNA) 的牛市吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1.5},"content_text":"CareDx reported third quarter 2026 revenue of US$139.36 million and net income of US$19.29 million, raised full year 2026 revenue guidance to US$520 million to US$530 million, and highlighted new KOAR registry data linking AlloSure Kidney donor derived cell free DNA patterns to three year kidney allograft outcomes. The KOAR findings suggest AlloSure Kidney may help flag subclinical graft injury before function declines. The higher revenue outlook and recent inducement equity grants indicate management is leaning into demand for CareDx transplant testing and related services. We will look at how CareDx's raised 2026 revenue guidance reshapes the existing investment narrative built around transplant testing economics.  Scan beyond CareDx and review other transplant and healthcare testing players that screen strongly on balance sheets and fundamentals with this hand picked list of solid balance sheet and fundamentals (25 results). AdvertisementCareDx Investment Narrative Recap To be a shareholder in CareDx, you need to believe its transplant testing platform can keep gaining real world traction with clinicians and payers, while the firm preserves solid economics from its CLIA labs and software. The KOAR data reinforces the clinical role of AlloSure Kidney as a surveillance tool that may detect molecular injury before kidney function visibly worsens. The key short term swing factor is whether test volume and average revenue per test stay healthy enough to support the recently raised 2026 revenue outlook. The biggest near term risk remains a valuation reset, because CareDx trades on a premium P/E multiple and sentiment could change even if operations remain steady. The fresh KOAR publication is the most relevant update here. It ties early AlloSure Kidney dd cfDNA trajectories to three year graft outcomes in more than 1,100 recipients across 56 centers, with persistent or late elevations linked to higher rates of dysfunction, rejection, donor specific antibodies and allograft loss. For investors watching catalysts, this kind of peer reviewed outcome data can matter for adoption, guideline inclusion and reimbursement stability, which all sit behind test demand and margins. It also complements the recent revenue growth, profitability in 2026 year to date and higher full year guidance, though it does not change the valuation and execution risks already present. CareDx's narrative projects US$701.4 million revenue and US$80.6 million earnings by 2029. This assumes 12.1% yearly revenue growth and an earnings decrease of US$48 million from US$128.6 million today. Uncover how CareDx's fair value indicates a 19% potential upside to its current price, which could narrow quickly. NasdaqGM:CDNA 1-Year Stock Price Chart Exploring Other Perspectives One alternate story on CareDx focuses less on KOAR style clinical momentum and more on valuation risk. The most cautious analysts were working off roughly US$651.5 million of revenue and US$44.2 million of earnings by 2029, and saw fair value about 10% below the market. That is a much harsher view on future economics. These estimates all pre date the new registry data and raised guidance, so it is worth comparing them with fresher assumptions and seeing which narrative you find more reasonable. Explore 3 other CareDx fair value estimates, including one that suggests it could be worth just $81.00. Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and analysis.  A great starting point for your CareDx research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for CareDx. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate CareDx's overall financial health at a glance.  Looking for more investment ideas beyond CareDx? CareDx may sit at the center of your watchlist today, but your overall results usually depend on the mix of companies you own. A focused screener can help you quickly surface stocks that line up with your risk tolerance, income needs, or preference for strong financial footing.  For investors evaluating potential mispricing, you can start with a curated group of quality businesses trading on what may look like attractive valuations through the 36 high quality undervalued stocks. If income stability matters to you, you may use the 7 dividend fortresses to review companies with higher yields and resilient cash flows. When capital preservation is the priority, you can filter for businesses that combine healthier balance sheets with lower risk profiles by running the 31 resilient stocks with low risk scores.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681844335","isCrawlerRequest":true}